Ovid Therapeutics Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on January 19, 2018, by Ovid Therapeutics Inc., a Delaware corporation. The report details compensation decisions made by the Compensation Committee of the Board of Directors regarding the company's named executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
Material Changes and Compensation Details
The Compensation Committee approved 2017 cash bonuses, 2018 annual base salaries (effective January 1, 2018), 2018 bonus targets, and equity awards for three executives:
| Executive | 2017 Cash Bonus | 2018 Base Salary | 2018 Bonus Target | 2018 Option Grant |
|---|---|---|---|---|
| Jeremy M. Levin (CEO) | $218,875 | $530,450 | 50% | 290,000 shares |
| Amit Rakhit (CMO) | $157,590 | $401,700 | 35% | 95,000 shares |
| Dirk Haasner (SVP) | $88,374 | $348,140 | 30% | 30,000 shares |
Equity Award Terms:
- Exercise Price: $9.18 per share (closing price on January 19, 2018).
- Term: 10 years from the grant date.
- Vesting Schedule: 25% vests on the one-year anniversary of the grant date; the remaining 75% vests in 36 equal monthly installments thereafter, contingent on continued service.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks and contingencies beyond the standard vesting conditions tied to continued employment.
Key Facts for Investor Verification
- Verify the total cash outflow for 2017 bonuses ($464,839) and the annual salary increase impact on 2018 operating expenses.
- Confirm the dilution impact of the 415,000 new stock options granted at an exercise price of $9.18.
- Review the company's 2017 Equity Incentive Plan to ensure sufficient shares were available for these grants.
- Monitor the vesting schedule to understand future retention liabilities for the CEO, CMO, and SVP.